Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Respiratory Infections, Recurrent, Chronic: early-phase trial registry

1 of 1 indexed Respiratory Infections, Recurrent, Chronic trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Respiratory Infections, Recurrent, Chronic: 1 US clinical trial tracked, 1 recruiting.

Respiratory Infections, Recurrent, Chronic is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Respirion Pharmaceuticals Pty, running 1 of these trials.

Enrollment posture brief

Registry condition respiratory-infections-recurrent-chronic

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Respiratory Infections, (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Respiratory Infections, Recurrent, Chronic

Respiratory Infections, Recurrent, Chronic lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Respiratory Infections, Recurrent, Chronic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Respiratory Infections, Recurrent, Chronic is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

Named interventions

Most-linked intervention names on Respiratory Infections, Recurrent, Chronic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Tobramycin inhalation solution Drug
1 trials
RSP-1502 Drug
1 trials

US sites by state

Facility locations filed on Respiratory Infections, Recurrent, Chronic trials. A trial with sites in several states counts in each.

Texas 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New York 1 trials
Missouri 1 trials
Minnesota 1 trials
Louisiana 1 trials
Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Respiratory Infections, Recurrent, Chronic page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Respiratory Infections, Recurrent, Chronic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Respirion Pharmaceuticals Pty sponsors the most Respiratory Infections, Recurrent, Chronic trials on record, review their full trial history before evaluating a specific study. See Respirion Pharmaceuticals Pty's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Respiratory Infections, Recurrent, Chronic condition card totals 1 registered trials; most-linked intervention Tobramycin inhalation solution; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.